Overview

Santus Laboratories (owned by HealthEdge Partners) manufactures and sells dermatology products to the institutional market, including hospitals and long-term care. Santus’ key product is a proprietary and highly regarded product, Lantiseptic.

Santus was purchased by DermaRite (owned by Tailwind Capital Group) to acquire the right to manufacture, market and sell Lantiseptic. Lantiseptic will enable DermaRite to extend their product portfolio and provide a differentiated product to the institutional market.

Significance

Will provide DermaRite the ability to market a differentiated and growing dermatology product.

Provided DermaRite with some new manufacturing capabilities.

Crosstree’s Role

Sole advisor to Santus/Healthedge